Delving into the Latest Updates on Fluorothymidine F-18 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms

Target-

Mechanism

PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [1]

Active Indication

Acute Lymphoblastic LeukemiaBrain Cancer

Inactive Indication

Anus NeoplasmsBrain metastasesBreast Cancer+ [12]

Originator Organization

National Cancer Institute

Active Organization

The Children's Hospital Corp.

Advanced Innovative Partners IncStartup

Inactive Organization

National Institutes of HealthUNC Lineberger Comprehensive Cancer Center

National Cancer Institute

+ [4]

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC10H13FN2O4

InChIKeyUXCAQJAQSWSNPQ-ZIVQXEJRSA-N

CAS Registry287114-80-1

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.

Start Date19 Jan 2023

Sponsor / Collaborator

University of Oklahoma

[+1]

NCT04309552 / RecruitingPhase 1IIT

A Phase-I Trial for Simultaneous Imaging of Tumor Hypoxia and Proliferation in Patients With Treatment- Naïve High-Grade Glioma

This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia). FLT PET (Fluorodeoxythymidine-PET) allows researchers to study the increase in the number of cells as a result of cell growth and cell division (proliferation). Tumors that have low oxygen levels and/or are dividing fast shall resist to standard cancer treatment. The study will compare FMISO PET and FLT PET imaging techniques with molecular biomarkers of hypoxia, angiogenesis, and cellular proliferation in tissue. proliferation).This information could help researchers develop new treatment techniques to better treat cancer.

Start Date01 Feb 2021

Sponsor / Collaborator

Weill Medical College of Cornell University

NCT04067115 / Active, not recruitingPhase 1/2IIT

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination With Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

This study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a Positron Emission Tomography (PET) scan to help evaluate the effect of treatment.
Phase I was completed on 11/16/2022. Phase II is actively recruiting.

Start Date05 Jan 2021

Sponsor / Collaborator

Sarcoma Alliance for Research through Collaboration

[+3]

100 Clinical Results associated with Fluorothymidine F-18

Login to view more data

100 Translational Medicine associated with Fluorothymidine F-18

Login to view more data

100 Patents (Medical) associated with Fluorothymidine F-18

Login to view more data

31

Literatures (Medical) associated with Fluorothymidine F-18

01 Nov 2023·Japanese Journal of Radiology

Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET

Article

Author: Oshima, Sonoko ; Sano, Kohei ; Nakamoto, Yuji ; Arakawa, Yoshiki ; Fushimi, Yasutaka ; Okuchi, Sachi ; Sakata, Akihiko ; Mineharu, Yohei ; Wang, Yang ; Hinoda, Takuya ; Nakajima, Satoshi ; Tanji, Masahiro ; Shimizu, Yoichi ; Yoshida, Kazumichi ; Ishimori, Takayoshi ; Otani, Sayo

AbstractPurposeThis study aimed to investigate the uptake characteristics of 18F-fluoromisonidazole (FMISO), in mutant-type isocitrate dehydrogenase (IDH-mutant, grade 3 and 4) and wild-type IDH (IDH-wildtype, grade 4) 2021 WHO classification adult-type diffuse gliomas.Materials and methodsPatients with grade 3 and 4 adult-type diffuse gliomas (n = 35) were included in this prospective study. After registering 18F-FMISO PET and MR images, standardized uptake value (SUV) and apparent diffusion coefficient (ADC) were evaluated in hyperintense areas on fluid-attenuated inversion recovery (FLAIR) imaging (HIA), and in contrast-enhanced tumors (CET) by manually placing 3D volumes of interest. Relative SUVmax (rSUVmax) and SUVmean (rSUVmean), 10th percentile of ADC (ADC10pct), mean ADC (ADCmean) were measured in HIA and CET, respectively.ResultsrSUVmean in HIA and rSUVmean in CET were significantly higher in IDH-wildtype than in IDH-mutant (P = 0.0496 and 0.03, respectively). The combination of FMISO rSUVmean in HIA and ADC10pct in CET, that of rSUVmax and ADC10pct in CET, that of rSUVmean in HIA and ADCmean in CET, were able to differentiate IDH-mutant from IDH-wildtype (AUC 0.80). When confined to astrocytic tumors except for oligodendroglioma, rSUVmax, rSUVmean in HIA and rSUVmean in CET were higher for IDH-wildtype than for IDH-mutant, but not significantly (P = 0.23, 0.13 and 0.14, respectively). The combination of FMISO rSUVmean in HIA and ADC10pct in CET was able to differentiate IDH-mutant (AUC 0.81).ConclusionPET using 18F-FMISO and ADC might provide a valuable tool for differentiating between IDH mutation status of 2021 WHO classification grade 3 and 4 adult-type diffuse gliomas.

01 Nov 2023·International journal of hematology

Hematopoiesis in the spleen after engraftment in unrelated cord blood transplantation evaluated by ¹⁸F-FLT PET imaging.

Article

Author: Hosono, Naoko ; Kiyono, Yasushi ; Yamauchi, Takahiro ; Tsujikawa, Tetsuya ; Okazawa, Hidehiko ; Araie, Hiroaki

Cord blood is an important donor source for allogeneic hematopoietic stem cell transplantation (allo-HSCT), with its unique composition and quality of hematopoietic cells. The proliferation site and potency of infused hematopoietic stem cells in humans may vary between stem cell sources. We investigated this possibility in a prospective, exploratory study to assess hematopoietic dynamics using the radiopharmaceutical 3'-deoxy-3'-¹⁸F-fluorothymidine (¹⁸F-FLT), a thymidine analog used in positron emission tomography imaging, before allo-HSCT and on days 50 and 180 after allo-HSCT. We evaluated 11 patients with hematological malignancies who underwent allo-HSCT [five with peripheral blood stem cell transplantation (PBSCT) and six with unrelated cord blood transplantation (UCBT)]. Before allo-HSCT, ¹⁸F-FLT uptake did not differ between the two groups. At day 50, ¹⁸F-FLT uptake in the spleen was significantly greater in the UCBT group than in the PBSCT group (p = 0.0043), with no difference in whole-body bone marrow. At day 180, the differences in spleen uptake had diminished, and there were no differences between groups in whole-body bone marrow or the spleen, except for the sternum. The persistence of splenic hematopoiesis after engraftment in the UCBT group may reflect the complex systemic homing and proliferation mechanisms of cord blood hematopoietic cells.

01 Feb 2023·Journal of Magnetic Resonance Imaging

Breast PET/MRI Hybrid Imaging and Targeted Tracers

Review

Author: Romeo, Valeria ; Pinker, Katja ; Helbich, Thomas H.

The recent introduction of hybrid positron emission tomography/magnetic resonance imaging (PET/MRI) as a promising imaging modality for breast cancer assessment has prompted fervent research activity on its clinical applications. The current knowledge regarding the possible clinical applications of hybrid PET/MRI is constantly evolving, thanks to the development and clinical availability of hybrid scanners, the development of new PET tracers and the rise of artificial intelligence (AI) techniques. In this state‐of‐the‐art review on the use of hybrid breast PET/MRI, the most promising advanced MRI techniques (diffusion‐weighted imaging, dynamic contrast‐enhanced MRI, magnetic resonance spectroscopy, and chemical exchange saturation transfer) are discussed. Current and experimental PET tracers (18F‐FDG, 18F‐NaF, choline, 18F‐FES, 18F‐FES, 89Zr‐trastuzumab, choline derivatives, 18F‐FLT, and 68Ga‐FAPI‐46) are described in order to provide an overview on their molecular mechanisms of action and corresponding clinical applications. New perspectives represented by the use of radiomics and AI techniques are discussed. Furthermore, the current strengths and limitations of hybrid PET/MRI in the real world are highlighted.Evidence Level2Technical EfficacyStage 2

100 Deals associated with Fluorothymidine F-18

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Fluorothymidine F-18	-	DB14930

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain Cancer	Phase 2	US	The Children's Hospital Corp.	01 Oct 2010
Lymphoma	Phase 2	US	National Cancer Institute	29 Sep 2008
Prostatic Cancer	Preclinical	US	National Institutes of Health	01 Oct 2012
Brain metastases	Preclinical	US	Angiochem, Inc.	01 Oct 2011
Breast Cancer	Preclinical	-	Merck Sharp & Dohme Corp.	08 Apr 2010
Laryngeal Neoplasms	Preclinical	US	National Institutes of Health	01 Mar 2008
Mouth Neoplasms	Preclinical	US	National Institutes of Health	01 Mar 2008
Oropharyngeal Neoplasms	Preclinical	US	National Institutes of Health	01 Mar 2008
Squamous Cell Carcinoma of Head and Neck	Preclinical	US	National Institutes of Health	01 Mar 2008
Anus Neoplasms	Discovery	US	National Institutes of Health	01 Oct 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01244737 (CTgov)	Phase 2	Brain Cancer	50	[18F] FLT (New Diagnosis of Brain Tumor)	dfhlwmgqtw(wwzzeknzjr) = howymqrnlj nsgvzldiqf (znebzdtqpj, dcclrvmvnl - xbtylyqbdg) View more	-	11 Jul 2024
NCT01244737 (CTgov)	Phase 2	Brain Cancer	50	[18F] FLT (Possible Recurrent Brain Tumor)	dfhlwmgqtw(wwzzeknzjr) = rlvqhamqpu nsgvzldiqf (znebzdtqpj, eiuoolccwh - knnztfnngz) View more	-	11 Jul 2024
NCT03318497 (CTgov)	Phase 2	Pancreatic adenocarcinoma	6	Computed Tomography+3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT	(vlnilhhrwp) = nbsrlayvwu rcfjaulglo (sprlulbjsz, mcuixqaofc - vvhnxgahen) View more	-	08 Nov 2022
NCT01399658 (CTgov)	Phase 2	Vagina Carcinoma \| Uterine Cervical Cancer \| Vulvar Neoplasms	93	Image-guided brachytherapy+3'-Deoxy-3'-18f-Fluorothymidine	fumsvmmqwh(mthdbxpwnp) = dpthyjqeic lglxnwgpif (aqjuhltppu, afaddlmjhn - jizyvzickv) View more	-	02 Mar 2022
NCT00979810 (CTgov)	Not Applicable	High grade glioma	11	18F-FLT PET Scan	pbczxpdjdf(bdjnhsaphj) = hsczagplcm eeowqkxurl (sbanpdqvph, nydiucctzs - gufcnsweue) View more	-	17 Dec 2020
ISC2019	Not Applicable	Ischemic stroke	-	F-18-fluorothymidine (Rats subjected to transient middle cerebral artery occlusion (MCAO))	mujtoqikhu(aoqkjltaju) = cerebral FLT binding activity gradually declined from post MCAO day 7 to day 28 in the infarcted brain ercseduozl (ovmvapvogp ) View more	-	01 Feb 2019
NCT00721799 (CTgov)	Phase 2	Squamous Cell Carcinoma of Head and Neck \| Laryngeal Neoplasms \| Oropharyngeal Neoplasms \| Mouth Neoplasms	33	18F-Fluorothymidine PET scan	ciaoivsxlz(rkylualkcm) = tqmqiphbbp xwkjkmqwgl (tuqwocxoov, tybsycqpuw - bxoymjihrs) View more	-	03 Oct 2017
NCT01717391 (CTgov)	Phase 2	Endometrial Carcinoma \| Prostatic Cancer \| Pelvic Neoplasms \| Uterine Cervical Cancer \| Anus Neoplasms	36	FLT (Basline FLT PET/CT (All Subjects))	vssthlnryk(piclaylebt) = gsryaxtale tnfsjitjzy (huflkzfuxy, feicawaluz - jzqlgvkypm) View more	-	05 Sep 2017
NCT01717391 (CTgov)	Phase 2		36	FLT (FLT PET/CT)	ocxtuohldb(qxyrtnpdpv) = xelfiihsgq oolkjxicxc (vvgwqlgdey, jhyspukayt - qudvlarerr) View more	-	05 Sep 2017
NCT00572728 (ACRIN 6688, CTgov)	Phase 2	Locally advanced breast cancer \| Invasive Mammary Carcinoma \| Breast Cancer 3	90	PET+18F-FLT	dwgaapdvra(cxqiispudf) = zvkrhozdtd eluhkolgau (sflpdimycl, wogfbjbkzg - xhumkzlpvk) View more	-	20 Jan 2016
NCT00572728 (ACRIN 6688, Pubmed \| J Nucl Med)	Phase 2	Breast Cancer Neoadjuvant	90	3'-Deoxy-3'-18F-Fluorothymidine	ozgpabqbco(omiafsymdb): P-Value = 0.05	-	01 Nov 2015
NCT00572728 (ACRIN 6688, Pubmed \| J Nucl Med)	Phase 2	Breast Cancer Neoadjuvant	90	Neoadjuvant Chemotherapy	ozgpabqbco(omiafsymdb): P-Value = 0.05	-	01 Nov 2015
JPRN-UMIN000009329 (ASCO2015)	Phase 2	Stomach Cancer	20	<sup>18</sup>F-fluorothymidine (<sup>18</sup>F-FLT) (18F-FLT PET/CT)	nfiwakdmrk(obdfowcipj) = zbzonkmaxf yplujxibmm (plthadoxnd )	-	20 May 2015